Affymetrix (NASDAQ:AFFX) says Q3 revenue will be about $80M, short of consensus $85M, due to concerns about tighter academic funding globally and euro weakness. Some $18M will come from its eBioscience business, without which revenues will be "flat to slightly down" for the year. Results are due after the close Oct. 31.